Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2021, with a specific reporting date of October 14, 2021. The document serves as a transaction notification regarding dealings by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, or debt metrics for the company. It exclusively details specific share transactions executed on October 11, 2021:
- Transaction Type: Increase in notional interest in Ordinary Shares and American Depositary Shares (ADSs) via the re-investment of dividends paid on October 7, 2021, under the Deferred Annual Bonus Plan.
- Ordinary Shares Price: GBP 14.0080 per share (London Stock Exchange).
- ADS Price: USD 38.6600 per ADS (New York Stock Exchange).
- Total Volume: The filing lists individual transaction volumes for 15 executives, ranging from 47 to 2,365 shares/ADSs per individual.
Material Changes
No material changes to the company's financial position, operations, or strategy are reported in this filing. The document strictly reports routine, plan-driven share acquisitions by executives and does not provide comparative data against prior periods.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of insider trading activity compliant with market rules.
Investor Verification Checklist
- Verify that the share purchases were executed automatically under the Deferred Annual Bonus Plan and not as discretionary open-market trades.
- Confirm the dividend payment date of October 7, 2021 aligns with the company's declared dividend schedule.
- Check the London Stock Exchange and New York Stock Exchange closing prices for October 11, 2021, to validate the transaction prices of GBP 14.0080 and USD 38.6600.
- Review the full list of PDMRs involved to ensure no unexpected senior leadership changes are implied by the transaction list.